{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:46:18Z","timestamp":1779119178286,"version":"3.51.4"},"reference-count":14,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>We determined the pharmacokinetics of efavirenz in plasma and cerebrospinal fluid (CSF) over a 24-h dosing interval in a patient who had undergone a lumbar drain because of cryptococcal meningitis. Drug concentrations were determined by high-performance liquid chromatography-tandem mass spectrometry in paired CSF (<jats:italic>n<\/jats:italic>= 24) and plasma (<jats:italic>n<\/jats:italic>= 25) samples. The median plasma efavirenz concentration was 3,718 ng\/ml (range, 2,439 to 4,952), and the median CSF concentration was 16.3 ng\/ml (range, 7.3 to 22.3). The CSF\/plasma area-under-the-curve ratio was 0.0044 corresponding to a CSF penetration of 0.44% of plasma.<\/jats:p>","DOI":"10.1128\/aac.06311-11","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T05:39:27Z","timestamp":1339479567000},"page":"4583-4585","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":25,"title":["Efavirenz Pharmacokinetics in Cerebrospinal Fluid and Plasma over a 24-Hour Dosing Interval"],"prefix":"10.1128","volume":"56","author":[{"given":"Aylin","family":"Yilmaz","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Watson","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Dickinson","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Back","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"18th Conference on Retroviruses and Opportunistic Infections","author":"Acosta E","year":"2011","unstructured":"AcostaE . 2011. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/498310"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jac\/dkq434","article-title":"Efavirenz concentrations in CSF exceed IC50 for wild-type HIV","volume":"66","author":"Best BM","year":"2010","unstructured":"BestBM . 2010. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J. Antimicrob. Chemother. 66:354\u2013357.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/13550280490521078"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10827"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1468-1293.2001.00056.x","article-title":"Antiretroviral treatment of central nervous system HIV-1 infection: a review","volume":"2","author":"Gisslen M","year":"2001","unstructured":"GisslenM HagbergL. 2001. Antiretroviral treatment of central nervous system HIV-1 infection: a review. HIV Med. 2:97\u2013104.","journal-title":"HIV Med."},{"key":"e_1_3_2_8_2","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas DW","year":"2004","unstructured":"HaasDW . 2004. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18:2391\u20132400.","journal-title":"AIDS"},{"key":"e_1_3_2_9_2","first-page":"66","volume-title":"Principles of physiology","author":"Levy MN","year":"1990","unstructured":"LevyMN StantonBA KoeppenMD. 1990. Membranes are composed of lipids and second messengers and signals, p 66\u201367. In BerneRM LevyMN (ed), Principles of physiology. C. V. Mosby Co, New York, NY."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101050-00011"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/QAD.0b013e328133f285","article-title":"Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies","volume":"21","author":"May M","year":"2007","unstructured":"MayM . 2007. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 21:1185\u20131197.","journal-title":"AIDS"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69152-6"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/135965350501000607","article-title":"Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment","volume":"10","author":"Mellgren A","year":"2005","unstructured":"MellgrenA . 2005. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir. Ther. 10:701\u2013707.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/QAD.0b013e3283354a7b","article-title":"Cognitive dysfunction in HIV patients despite long-standing suppression of viremia","volume":"24","author":"Simioni S","year":"2010","unstructured":"SimioniS . 2010. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24:1243\u20131250.","journal-title":"AIDS"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/314945"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.06311-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.06311-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T09:13:27Z","timestamp":1687511607000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.06311-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1128\/AAC.06311-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.06311-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"2011-12-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-04-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-08-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}